BackAllena Pharmaceuticals Overview

Allena Pharmaceuticals Other Current Liabilities

Latest other current liabilities for ALNA: $7.8M.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$7.77M
56.23% YoYΔ $2.80M vs prior year quarter

Peer trimmed avg / median

Loading

Allena Pharmaceuticals Other Current Liabilities History

Loading

Allena Pharmaceuticals vs. peers: Other Current Liabilities Comparison

Loading

Allena Pharmaceuticals Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Allena Pharmaceuticals (ALNA) FAQ

The latest other current liabilities for ALNA is $7.8M as of June 2022. That compares with $5M in the prior-year period — up 56.2% year over year. Investors often review this figure alongside Allena Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, ALNA's other current liabilities moved from $5M to $7.8M — a 56.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Allena Pharmaceuticals's operating scale or balance-sheet position.

A other current liabilities figure of $7.8M for ALNA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ALNA's other current liabilities ($7.8M), review year-over-year change from $5M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Allena Pharmaceuticals's other current liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.